Video Author: Jennifer Smith Publish date: April 18, 2019
NEWPORT BEACH, CALIF. – Ruxolitinib plus decitabine won’t proceed to a phase 3 trial for the treatment of accelerated or blast phase myeloprolifera...
Video Author: Jennifer Smith Publish date: April 16, 2019
NEWPORT BEACH, CALIF. – Dr. John F. DiPersio discusses preclinical research testing CAR T-cell therapies in T-cell malignancies.
News Author: Jennifer Smith Publish date: April 9, 2019
Two of eight patients treated with the investigational gene therapy SB-525 have achieved normal factor VIII levels, according to interim study resu...
News Author: Jennifer Smith Publish date: April 8, 2019
In situ vaccination induced regression of tumors that were directly targeted, as well as tumors that were not treated, in a small study of patients...
Article Author: Jennifer Smith Publish date: April 5, 2019
Dr. Warner K. Huh is named president of the Society of Gynecologic Oncology, and appointments are made at AACR, NCCN, and MD Anderson.
News Author: Jennifer Smith Publish date: April 5, 2019
Polatuzumab vedotin plus rituximab produced more durable responses than did pinatuzumab vedotin plus rituximab in patients with relapsed or refract...
News Author: Jennifer Smith Publish date: April 2, 2019
The combination of busulfan plus melphalan produced superior progression-free survival but no overall survival advantage in the phase 3 trial. ...
News Author: Jennifer Smith Publish date: March 25, 2019
The researchers will be recognized at the annual meeting of the American Association for Cancer Research in Atlanta.
Article Author: Jennifer Smith Publish date: March 23, 2019
“This is the first study, to our knowledge, to show such an interaction between race and survival being mediated by one particular treatment modali...
News Author: Jennifer Smith Publish date: March 22, 2019
HONOLULU – Combination lenvatinib and paclitaxel produced an objective response rate of 65%, and most adverse events were grade 1 or 2.
News Author: Jennifer Smith Publish date: March 19, 2019
HONOLULU – The perceived risk of HPV-related cancer appears to overcome variables that typically impede access to HPV...
News Author: Jennifer Smith Publish date: March 19, 2019
HONOLULU – Tumor response rate was 40% with pembrolizumab plus bevacizumab and oral metronomic cyclophosphamide in patients with recurrent epitheli...
News Author: Jennifer Smith Publish date: March 18, 2019
HONOLULU - Combining avelumab with pegylated liposomal doxorubicin may provide a survival benefit in certain patients with platinum-resistant or re...
News Author: Jennifer Smith Publish date: March 17, 2019
HONOLULU – A small survey suggests financial toxicity may be common among gynecologic cancer patients starting a new line of treatment.
News Author: Jennifer Smith Publish date: March 16, 2019
HONOLULU – The median overall survival was better among patients who received brachytherapy for 8 weeks or longer com...
